hantaan
viru
htnv
infect
caus
sever
hemorrhag
fever
renal
syndrom
hfr
human
associ
high
fatal
rate
cytotox
cell
ctl
respons
contribut
viru
elimin
howev
date
hla
class
allelerestrict
htnv
glycoprotein
gp
epitop
recogn
ctl
report
limit
understand
ctl
respons
htnv
infect
human
studi
htnv
gp
ninem
epitop
may
bind
hlaa
molecul
predict
use
bima
syfpeithi
databas
seven
epitop
demonstr
bind
hlaa
molecul
high
affin
via
cell
bind
assay
success
use
synthes
peptidehlaa
tetram
result
tetram
stain
show
frequenc
epitopespecif
ctl
higher
patient
milder
hfr
indic
epitop
may
induc
protect
ctl
respons
htnv
infect
immunospot
analysi
confirm
immunoreact
epitop
elicit
epitopespecif
ctl
respons
htnv
challeng
trial
signific
inhibit
htnv
replic
character
lower
level
antigen
rna
load
observ
major
target
organ
liver
spleen
kidney
k
b
transgen
mice
prevaccin
nonapeptid
vmaslvwpv
sltecptfl
liwtgmidl
importantli
exhibit
best
abil
induc
protect
ctl
respons
show
promin
effect
kidney
potenti
prevent
kidney
injuri
htnv
infect
taken
togeth
result
highlight
htnv
gpderiv
hlaa
epitop
could
elicit
protect
ctl
respons
viru
epitop
htnv
patient
severecrit
sever
tend
weak
tcell
respons
araki
el
al
found
htnv
infect
maintain
presenc
high
titer
neutral
antibodi
indic
antibodi
alon
elimin
viru
notabl
np
undetect
adopt
transfer
htnvspecif
cell
suggest
htnvspecif
cell
major
effector
cell
viru
contribut
clearanc
htnv
moreov
individu
infect
puuv
htnv
maintain
virusspecif
memori
ctl
mani
year
acut
infect
reveal
import
ctl
prevent
second
infect
therefor
identif
ctl
epitop
explor
mechan
ctl
respons
htnv
infect
desir
develop
effect
vaccin
hfr
date
htnvspecif
ctl
epitop
identifi
distribut
np
earli
research
identifi
three
ctl
epitop
htnv
np
recent
also
report
eight
htnv
npspecif
ctl
epitop
restrict
variou
hla
allel
includ
demonstr
gp
major
antigen
involv
induct
neutral
antibodi
play
import
role
elicit
humor
immun
respons
protect
infect
anim
human
lethal
hantaviru
infect
howev
kilpatrick
et
al
discov
patient
hp
earli
snv
infect
show
higher
frequenc
gc
epitopespecif
cell
np
epitopespecif
cell
tobia
et
al
found
andv
gnderiv
peptid
immunodomin
epitop
elicit
specif
respons
compar
np
gc
npspecif
respons
declin
gnspecif
respons
remain
readili
detect
year
infect
henc
assum
htnv
gpderiv
peptid
may
function
epitop
induc
effect
ctl
respons
htnv
infect
recent
htnv
gnderiv
b
restrict
ctl
epitop
itslfsll
identifi
confirm
hypothesi
specif
ctl
htnv
gpderiv
epitop
howev
b
restrict
ctl
epitop
may
induc
parallel
respons
human
scream
hla
class
allelerestrict
epitop
could
provid
addit
help
better
understand
recognit
htnv
human
ctl
importantli
chines
han
popul
differ
region
similar
allel
divers
among
hlaa
common
hla
class
allel
henc
identif
hlaa
htnv
gpspecif
ctl
epitop
could
promis
broadli
applic
approach
prevent
htnv
infect
present
studi
identifi
seven
novel
htnv
gpderiv
hlaa
ninem
ctl
epitop
demonstr
epitop
could
induc
specif
ctl
respons
vitro
importantli
three
epitop
mucou
membran
renal
failur
typic
oligur
stage
sever
sever
effus
bulbar
conjunctiva
either
pleura
peritoneum
uremia
hemorrhag
skin
mucou
membran
renal
failur
oliguria
urin
output
mlday
day
anuria
urin
output
mlday
day
critic
follow
symptom
sever
diseas
viscer
hemorrhag
refractori
shock
heart
failur
pulmonari
edema
brain
edema
sever
secondari
infect
sever
renal
failur
oliguria
urin
output
mlday
day
anuria
urin
output
mlday
day
blood
urea
nitrogen
level
mmoll
patient
kidney
diseas
diabet
cardiovascular
diseas
autoimmun
diseas
hematolog
diseas
viral
hepat
liver
diseas
exclud
studi
ensur
sampl
size
statist
analys
combin
patient
accord
diseas
sever
mildmoder
severecrit
group
comparison
case
number
patient
sever
degre
mildmoder
severecrit
respect
accord
clinic
observ
ill
could
divid
acut
phase
phase
within
day
fever
onset
earli
oligur
stage
convalesc
phase
diuret
convalesc
stage
peripher
blood
sampl
intraven
collect
hospit
hfr
patient
hlaa
subject
seroneg
htnv
normal
control
nc
peripher
blood
mononuclear
cell
pbmc
isol
blood
sampl
use
standard
ficollhypaqu
sigmaaldrich
mo
usa
densiti
gradient
centrifug
pbmc
stain
fluorescein
phycoerythrin
pe
label
antihuman
hlaa
monoclon
antibodi
mab
clone
biolegend
test
whether
hlaa
express
flow
cytometri
facscan
bd
bioscienc
hlaa
pbmc
select
appli
follow
assay
htnv
strain
kindli
provid
depart
microbiolog
univers
commerci
hfr
inactiv
vaccin
youerjian
zhejiang
tianyuan
biopharmaceut
co
ltd
china
deriv
mixtur
htnv
seov
provid
bival
purifi
hfr
vaccin
bioinformat
molecular
analysi
section
bima
hla
peptid
bind
predict
deriv
experiment
measur
halftim
dissoci
rate
peptidehla
complex
syfpeithi
databas
contain
collect
mhc
class
class
ii
ligand
peptid
motif
human
speci
bima
syfpeithi
http
wwwbimascitnihgovmolbiohlabind
http
chosen
immun
b
transgen
tg
mice
could
elicit
immun
respons
inhibit
htnv
replic
vivo
find
provid
crucial
inform
character
tcell
immun
htnv
infect
may
advanc
design
safe
effect
htnv
peptid
vaccin
well
diagnosi
immunotarget
hfr
studi
approv
institut
review
board
fourth
militari
medic
univers
enrol
patient
guardian
sign
inform
consent
form
blood
collect
anim
test
perform
strict
accord
recommend
guid
care
tabl
accord
diagnost
criteria
prevent
treatment
strategi
hfr
describ
ministri
health
peopl
republ
china
sever
degre
hfr
diseas
could
classifi
four
clinic
type
mild
moder
sever
critic
mild
mild
renal
failur
without
obviou
oligur
stage
moder
obviou
symptom
effus
bulbar
conjunctiva
uremia
hemorrhag
skin
use
predict
hlaa
htnv
gp
ninem
epitop
input
amino
acid
sequenc
htnv
strain
genbank
access
number
databas
analysi
option
hlaa
ninem
peptid
base
result
predict
bima
syfpeithi
ninem
peptid
htnv
gp
synthes
puriti
assess
highperform
liquid
chromatographi
mass
spectrometri
cl
bioscientif
xian
china
peptid
vpillkali
htnv
np
confirm
ctl
epitop
restrict
hlab
previou
studi
synthes
uncorrel
peptid
control
ctl
epitop
fvvpillka
htnv
np
restrict
hlaa
synthes
posit
peptid
control
peptid
store
mm
concentr
repeat
freezethaw
avoid
lymphoblast
cell
line
cem
purchas
american
type
cultur
collect
cat
manassa
va
usa
cell
transporterassoci
cell
antigen
process
tap
defici
defect
endogen
mhc
class
present
although
cell
express
low
level
hlaa
molecul
normal
cultur
condit
express
hlaa
molecul
much
higher
level
bind
appropri
peptid
stabil
express
hlaa
cell
surfac
determin
bind
capabl
predict
htnv
gp
nonapeptid
hlaa
molecul
cell
bind
assay
perform
describ
elsewher
briefli
cell
incub
peptid
human
sigma
serumfre
rpmi
medium
h
express
hlaa
molecul
surfac
cell
determin
stain
pelabel
antihlaa
mab
clone
biolegend
detect
flow
cytometri
facscan
bd
bioscienc
result
present
fluoresc
index
fi
determin
follow
fi
mean
pe
fluoresc
given
peptid
mean
pe
fluoresc
without
peptid
mean
pe
fluoresc
without
peptid
fi
repres
highaffin
peptid
indic
stabl
combin
peptid
hlaa
molecul
surfac
cell
could
increas
mean
fluoresc
hlaa
molecul
least
onefold
peptidehlaa
tetram
stain
pelabel
hlaa
tetram
refold
separ
htnv
gp
nonapeptid
custom
quantobio
beij
china
refold
peptid
screen
hlaa
highaffin
htnv
gp
peptid
cell
bind
assay
pbmc
patient
stain
pelabel
hlaa
tetram
min
room
temperatur
subsequ
stain
fitclabel
antihuman
mab
clone
biolegend
antihuman
mab
clone
biolegend
min
ice
minimum
total
cell
acquir
gate
cell
tetram
tcell
gate
set
match
notetram
stain
isotyp
control
biolegend
compens
control
check
regularli
avoid
falseposit
result
individu
determin
experiment
setup
peripher
blood
mononuclear
cell
hlaa
hfr
patient
preserv
liquid
nitrogen
use
identif
htnv
gpderiv
ctl
epitop
perform
use
human
precoat
elispot
kit
dakew
biotech
compani
china
briefli
total
pbmc
rpmi
contain
fc
seed
well
plate
precoat
antihuman
antibodi
stimul
singl
peptid
peptid
mixtur
h
stimul
cell
remov
biotinyl
secondari
antibodi
ad
well
incub
h
next
unbound
secondari
antibodi
remov
sampl
incub
streptavidinhrp
h
final
unbound
streptavidinhrp
remov
aec
solut
ad
produc
spot
cell
phytohemagglutinin
dakew
biotech
compani
china
peptid
stimul
use
posit
neg
control
respect
spot
repres
epitopespecif
ctl
count
use
automat
elispot
reader
cellular
technolog
limit
usa
adjust
spotform
cell
sfc
subtract
neg
valu
express
pbmc
immun
b
tg
mice
peptid
b
tg
mice
subdivid
six
group
n
immun
tg
mice
htnv
gp
nonapeptid
carri
use
ntermin
fragment
murin
glycoprotein
adjuv
briefli
hlaa
peptid
ntermin
fragment
murin
emulsifi
togeth
complet
incomplet
freund
adjuv
difco
mixtur
immunogen
male
k
b
tg
mous
immun
prepar
mixtur
via
subcutan
inject
multipl
site
inject
volum
adjust
anim
three
immun
inject
administ
group
mice
interv
htnv
challeng
ten
day
last
immun
tg
mice
chal
leng
htnv
strain
intramuscular
inject
pfumous
fourth
day
htnv
challeng
tg
mice
sacrif
tissu
sampl
includ
cerebrum
heart
liver
spleen
lung
kidney
tg
mice
weigh
prepar
gram
millilit
tissu
suspens
pb
tissu
sampl
freezethaw
three
time
grind
centrifug
g
min
collect
supernat
hantaan
viru
antigen
supernat
tissu
sampl
tg
mice
detect
sandwich
elisa
antihtnv
np
mab
prepar
depart
microbiolog
univers
mab
use
coat
antibodi
horseradish
peroxidaseconjug
mab
use
detect
antibodi
supernat
normal
tissu
use
neg
control
first
add
prepar
supernat
duplic
well
incub
h
next
remov
supernat
wash
three
time
add
detect
antibodi
well
incub
h
remov
detect
antibodi
wash
three
time
add
tmb
substrat
well
incub
room
temperatur
final
add
stop
solut
sulfur
acid
measur
absorb
nm
standard
elisa
plate
reader
bior
positiveneg
pn
mean
ratio
posit
neg
absorb
valu
absorb
valu
exceed
neg
control
pn
consid
posit
signific
indic
htnvspecif
antigen
could
detect
sampl
major
target
organ
includ
liver
spleen
kidney
challeng
tg
mice
preserv
nonfrozen
tissu
rna
preserv
solut
solarbio
china
tissu
rna
organ
extract
use
rnaprep
pure
tissu
kit
tiangen
biotech
china
util
templat
revers
transcript
obtain
cdna
rtpcr
kit
takara
target
rna
sequenc
htnv
segment
detect
major
organ
util
sybr
realtim
quantif
pcr
kit
takara
follow
primer
htnv
forward
htnv
revers
mous
forward
mous
revers
result
record
cycl
time
ct
quantifi
statist
analysi
perform
use
spss
spss
inc
chicago
il
usa
graphpad
prism
softwar
version
graphpad
la
jolla
ca
usa
mannwhitney
u
test
student
ttest
use
paramet
comparison
two
subject
group
frequenc
epitopespecif
ctl
present
median
correspond
interquartil
rang
iqr
pvalu
twotail
p
consid
statist
signific
result
thirtyfour
htnv
gpderiv
hlaa
nonapeptid
predict
synthes
thirtyfour
htnv
gpderiv
hlaa
nonapeptid
predict
util
bima
syfpeithi
databas
rank
score
synthes
puriti
sequenc
locat
score
htnv
gpderiv
hlaa
nonapeptid
list
tabl
investig
bind
affin
nonapeptid
hlaa
molecul
cell
bind
assay
conduct
eight
predict
hlaa
nonapeptid
vliegkcfv
vmaslvwpv
vllsilcpv
slfsllpgv
sltecptfl
fllvlesil
liwt
gmidl
vigqciyti
increas
cell
surfac
express
hlaa
molecul
show
high
bind
affin
hlaa
molecul
character
fi
figur
notabl
nonapeptid
fi
exhibit
higher
bind
affin
among
nonapeptid
restrict
hlaa
use
posit
control
cell
line
without
peptid
use
neg
control
detail
inform
eight
nonapeptid
high
bind
affin
summar
tabl
frequenc
seven
hlaa
highaffin
htnv
gp
epitopespecif
cell
associ
sever
hfr
diseas
focus
eight
htnv
gp
nonapeptid
exhibit
highbind
affin
hlaa
molecul
util
synthes
peptidehlaa
tetram
com
plex
examin
whether
eight
nonapeptid
could
recogn
tcr
cell
hlaa
patient
hfr
seven
nonapeptid
success
use
synthes
tetram
wherea
nonapeptid
could
form
stabl
peptidehlaa
tetram
complex
thu
use
seven
peptidehlaa
tetram
determin
whether
nonapeptid
could
recogn
cell
quantifi
frequenc
nonapeptidespecif
cell
hlaa
patient
differ
sever
hfr
test
acut
phase
hospit
hlaa
subject
seroneg
htnv
serv
nc
epitopespecif
tetram
cell
could
detect
pbmc
indic
seven
nonapeptid
could
recogn
tcr
cell
figur
notabl
frequenc
seven
htnv
gp
nonapeptidespecif
cell
patient
mildmoder
diseas
significantli
higher
patient
sever
critic
diseas
nc
p
figur
indic
seven
htnv
gpderiv
epitop
might
induc
protect
ctl
respons
hlaa
hfr
patient
addit
epitop
cell
reveal
higher
frequenc
compar
epitopespecif
cell
patient
mildmoder
diseas
show
significantli
higher
frequenc
patient
severecrit
diseas
nc
p
figur
signific
differ
found
sv
flspecif
cell
patient
severecrit
diseas
nc
may
due
better
capabl
epitop
stimul
prolifer
epitopespecif
cell
seven
htnv
gp
nonapeptid
could
elicit
epitopespecif
tcell
respons
hlaa
hfr
patient
demonstr
seven
nonapeptid
could
bind
hlaa
molecul
recogn
tcr
form
mhcpeptidetcr
complex
next
assess
whether
nonapeptid
could
elicit
epitopespecif
tcell
respons
patient
hfr
thu
use
singl
peptid
peptid
mixtur
includ
seven
nonapeptid
stimul
pbmc
hlaa
patient
hfr
detect
frequenc
cell
elispot
assay
notabl
result
show
either
peptid
mixtur
singl
peptid
could
induc
product
pbmc
hfr
patient
vitro
figur
indic
seven
htnv
gp
epitop
could
effect
elicit
epitopespecif
tcell
respons
next
analyz
posit
respons
singlepeptid
level
limit
elispot
data
peptid
could
perform
statist
analysi
differ
sever
group
show
number
epitopespecif
ctl
make
comparison
hfr
patient
nc
pbmc
epitop
pbmc
epitop
pbmc
epitop
pbmc
epitop
pbmc
epitop
pbmc
epitop
nc
number
epitop
cell
larger
hfr
patient
nc
p
figur
notabl
remov
data
patient
severecrit
diseas
red
dot
number
epitop
cell
also
significantli
larger
nc
p
figur
indic
patient
milder
diseas
may
higher
tcell
respons
median
number
epitopespecif
ctl
differ
diseas
sever
group
also
show
tendenc
patient
milder
diseas
sever
epitopespecif
ctl
patient
sever
diseas
sever
tabl
supplementari
materi
immun
hlaa
htnv
gp
epitop
could
reduc
htnv
titer
tissu
supernat
b
tg
mice
htnv
challeng
sinc
found
higher
frequenc
epitopespecif
cell
associ
milder
diseas
sever
next
conduct
htnv
challeng
experi
determin
whether
epitopespecif
tcell
respons
could
provid
protect
mannwhitney
u
test
use
determin
signific
differ
two
group
black
line
repres
median
correspond
interquartil
rang
pvalu
p
consid
statist
signific
p
p
p
p
ns
indic
signific
differ
htnv
infect
vivo
achiev
goal
use
three
seven
epitop
show
higher
hlaa
affin
higher
frequenc
epitopespecif
cell
patient
mildmoder
sever
immun
b
tg
mice
subsequ
establish
model
htnv
infect
base
replic
viru
vivo
previou
studi
detect
htnv
titer
six
organ
htnvinfect
b
tg
mice
found
high
level
htnv
antigen
could
detect
liver
black
dot
repres
patient
mildmoder
diseas
sever
red
dot
repres
patient
severecrit
diseas
sever
number
epitopespecif
sfc
calcul
subtract
number
spot
neg
control
stimul
sampl
mannwhitney
u
test
use
determin
signific
differ
two
group
black
line
repres
median
correspond
interquartil
rang
pvalu
p
consid
statist
signific
p
p
ns
indic
signific
differ
spleen
kidney
lung
cerebrum
heart
tg
mice
suggest
liver
spleen
kidney
major
organ
infect
replic
htnv
b
tg
mice
consist
previou
result
detect
viru
found
lung
cerebrum
heart
six
group
immun
tg
mice
htnv
challeng
base
detect
htnv
antigen
tissu
supernat
elisa
figur
htnv
challeng
tg
mous
neg
control
group
inject
pb
show
evid
hightit
htnv
antigen
tissu
supernat
liver
spleen
kidney
wherea
differ
reduc
level
mean
viral
titer
observ
organ
mice
immun
hfr
vaccin
epitop
figur
compar
neg
control
tg
mice
immun
epitop
led
signific
decreas
mean
htnv
titer
supernat
liver
p
figur
immun
epitop
led
signific
decreas
liver
spleen
p
liver
p
spleen
figur
immun
epitop
led
signific
decreas
liver
kidney
p
liver
p
kidney
figur
importantli
epitop
mice
show
significantli
lower
level
detect
htnv
antigen
detect
lung
cerebrum
heart
six
group
immun
tg
mice
htnv
challeng
elisa
b
comparison
htnv
antigen
level
among
six
immun
group
tissu
supernat
liver
spleen
kidney
respect
posit
neg
pn
mean
ratio
posit
neg
absorb
valu
absorb
valu
exceed
neg
control
pn
consid
posit
signific
indic
htnvspecif
antigen
could
detect
sampl
student
ttest
use
statist
evalu
pvalu
p
consid
statist
signific
p
p
ns
indic
signific
differ
htnv
titer
liver
kidney
comparison
irrelev
control
peptid
tg
mice
p
liver
p
kidney
figur
similar
level
comparison
hfr
vaccineimmun
mice
figur
suggest
tcell
respons
induc
epitop
could
strongli
inhibit
viru
replic
clear
htnv
liver
kidney
immun
htnv
gp
epitop
could
inhibit
htnv
replic
b
tg
mice
protect
htnv
challeng
previou
result
indic
liver
spleen
kidney
b
tg
mice
target
organ
htnv
immun
htnv
gp
epitop
could
decreas
htnv
antigen
level
tissu
supernat
htnvinfect
tg
mice
protect
effect
evalu
htnv
gp
epitop
use
sensit
accur
assay
realtim
pcr
determin
htnv
segment
rna
load
target
organ
epitop
tg
mice
challeng
htnv
accord
htnv
antigen
detect
tg
mice
inject
pb
immun
control
peptid
show
high
htnv
rna
load
target
organ
detect
htnv
rna
load
observ
target
organ
mice
immun
hfr
vaccin
figur
notabl
detect
signific
differ
htnv
rna
load
tg
mice
immun
htnv
gp
epitop
mice
inject
pb
immun
control
peptid
htnv
rna
load
liver
spleen
kidney
mice
immun
epitop
significantli
lower
level
mice
inject
pb
immun
control
peptid
p
figur
indic
epitopespecif
tcell
respons
could
inhibit
htnv
replic
liver
spleen
kidney
tg
mice
hfr
inactiv
vaccineimmun
tg
mice
show
lower
htnv
rna
load
liver
spleen
compar
epitop
tg
mice
p
figur
interestingli
signific
differ
kidney
htnv
vaccineimmun
tg
mice
compar
htnv
rna
load
tg
mice
p
figur
suggest
epitop
might
induc
preponder
tcell
respons
kidney
inhibit
viru
replic
sinc
epitop
could
induc
tcell
respons
inhibit
htnv
replic
compar
htnv
rna
load
among
tg
mice
explor
epitop
strongest
protect
effect
differ
target
organ
liver
spleen
kidney
tg
mice
significantli
lower
htnv
rna
load
compar
tg
mice
p
figur
suggest
tcell
respons
stronger
effect
inhibit
htnv
replic
tcell
respons
lower
htnv
rna
load
observ
tg
mice
tg
mice
figur
indic
tcell
respons
might
play
critic
role
htnv
previous
report
eight
htnv
npderiv
ctl
epitop
demonstr
hlaa
ctl
epitop
fvvpillka
np
could
display
polyfunct
activ
mediat
effect
protect
respons
b
tg
mice
studi
first
identifi
seven
htnv
gpderiv
hlaa
ctl
epitop
base
high
bind
affin
hlaa
molecul
abil
bind
tcr
abil
elicit
ctl
respons
importantli
frequenc
seven
epitopespecif
ctl
higher
patient
mildmoder
sever
severecrit
sever
notabl
epitop
show
higher
bind
affin
hlaa
molecul
frequenc
epitopespecif
ctl
pbmc
hfr
patient
evid
indic
immun
epitop
success
gener
protect
ctl
respons
inhibit
htnv
infect
htnv
challeng
b
tg
mice
especi
immun
epitop
dramat
inhibit
htnv
replic
target
organ
liver
spleen
kidney
tg
mice
suggest
epitop
might
good
candid
use
design
effect
htnv
peptid
vaccin
htnv
vaccin
effect
mean
prevent
viral
infect
howev
individu
immun
hfr
vaccin
may
still
develop
hfr
diseas
due
limit
neutral
antibodi
secret
cellular
immun
respons
thu
develop
effect
htnv
vaccin
necessari
emerg
result
reveal
vaccin
strictli
elicit
immunodomin
epitopespecif
ctl
respons
could
effect
virus
vaccin
induc
immunodomin
subdomin
epitop
respons
significantli
less
protect
vaccin
elicit
immunodomin
epitopespecif
respons
suggest
tcell
immun
htnv
frontier
immunolog
wwwfrontiersinorg
decemb
volum
articl
increas
breadth
tcell
epitop
recognit
may
prevent
induct
optim
protect
ctl
immun
reduc
effici
host
immun
pathogen
secondari
ctl
expans
vaccin
mice
compet
antigen
access
antigenpres
cell
suppress
prime
protect
pathogenspecif
ctl
potenti
explain
subdomin
epitop
vaccin
could
reduc
immunodomin
epitopeinduc
ctl
respons
sinc
hfr
vaccin
potenti
elicit
immunodomin
subdomin
epitopespecif
ctl
respons
immun
inactiv
vaccin
may
restrict
induct
optim
ctl
respons
notabl
peptid
vaccin
avail
target
prevent
elicit
epitopespecif
ctl
respons
identif
protect
immunodomin
epitop
htnv
may
feasibl
design
safer
effect
vaccin
htnv
infect
chines
han
popul
develop
stabl
gene
polymorph
hla
b
loci
long
evolutionari
process
hlaa
allel
predomin
much
thu
focus
hlaa
immunodomin
epitop
demonstr
seven
htnv
gpderiv
hlaa
epitop
could
recogn
tcr
ctl
pbmc
hfr
patient
indic
epitop
present
hlaa
htnvinfect
cell
may
function
target
specif
ctl
interestingli
result
show
patient
mildmoder
hfr
sever
acut
phase
higher
frequenc
htnv
gp
epitopespecif
ctl
patient
severecrit
sever
suggest
epitopespecif
ctl
might
play
protect
role
reduc
sever
hfr
earli
time
point
recogn
epitop
present
htnvinfect
cell
tetram
result
less
approxim
frequenc
nc
mainli
patient
sever
critic
hfr
also
suggest
patient
lower
frequenc
htnv
gpspecif
ctl
earli
time
htnv
infect
may
develop
sever
hfr
result
consist
previou
studi
show
increas
vigor
htnv
npspecif
ctl
respons
correl
milder
hfr
studi
also
indic
protect
effect
ctl
respons
hamster
model
activ
tcell
immun
respons
respons
immunopathogenesi
hpslike
diseas
perhap
innat
immun
respons
either
elicit
infect
endotheli
cell
macrophag
neutrophil
contribut
diseas
mous
model
persist
infect
almost
cell
detect
mice
transient
infect
show
increas
function
htnvspecif
ctl
htnvspecif
tcell
respons
patient
sever
hfr
heavili
impair
earli
stage
infect
indic
initi
failur
mount
strong
tcell
respons
may
primari
caus
progress
acut
htnv
infect
sever
hfr
studi
remov
elispot
data
patient
severecrit
diseas
number
epitop
cell
significantli
larger
nc
indic
patient
milder
diseas
may
function
epitopespecif
cell
thu
function
htnv
epitopespecif
ctl
earli
time
point
htnv
infect
import
htnv
clearanc
prevent
hfr
develop
demonstr
seven
htnv
gp
nonapeptid
abl
induc
ctl
respons
consid
patient
milder
sever
higher
frequenc
epitopespecif
ctl
acut
phase
infect
specul
htnv
gp
epitopespecif
ctl
might
gener
earli
time
point
htnv
infect
elicit
effect
protect
ctl
respons
htnv
patient
milder
hfr
rather
sever
infect
howev
kilpatrick
et
al
identifi
three
hlab
ctl
epitop
snv
found
significantli
higher
frequenc
three
epitopespecif
ctl
patient
sever
hp
moder
hp
import
factor
influenc
balanc
protect
ctl
respons
contribut
viral
clearanc
intens
activ
ctl
may
trigger
immunolog
injuri
differ
hla
allel
restrict
viru
speci
may
consider
factor
impact
ctl
respons
diseas
outcom
taken
account
studi
ctl
respons
viru
infect
notabl
kilpatrick
studi
total
frequenc
three
snv
epitopespecif
ctl
reach
patient
sever
hp
patient
moder
hp
exceed
present
studi
frequenc
htnv
gp
epitopespecif
ctl
maintain
rel
lower
rang
previou
studi
also
show
htnv
np
epitop
ctl
also
contribut
milder
hfr
maintain
lower
frequenc
henc
frequenc
activ
specif
ctl
maintain
optimum
rang
may
appropri
way
elicit
effect
respons
viru
avoid
damag
host
notabl
studi
frequenc
seven
epitopespecif
ctl
test
elispot
assay
lower
test
tetram
stain
tuuminen
et
al
also
found
puuv
np
epitopespecif
ctl
measur
elispot
lower
acut
puuv
infect
indic
increas
epitopespecif
ctl
visual
direct
tetram
stain
may
readili
detect
vitro
function
assay
elsipot
tetram
stain
elispot
assay
met
valid
criteria
tetram
stain
show
better
precis
tetram
stain
mimic
molecular
interact
peptidehla
complex
tcr
initi
tcell
activ
vitro
elispot
assay
reli
function
readout
cytokin
secret
situ
enumer
respond
cell
overwhelm
amount
antigen
differ
threshold
peptid
stimul
may
drive
cell
apoptosi
activationinduc
cell
death
lead
clonal
exhaust
exhaust
termin
differenti
cell
could
die
lengthi
incub
h
produc
enough
measur
elispot
assay
tetram
stain
unrespons
cell
could
measur
may
explain
frequenc
epitopespecif
ctl
test
elispot
lower
ctl
dysfunct
state
could
restor
incub
suggest
cytokin
produc
th
cell
may
maintain
function
ctl
howev
antigenspecif
ctl
may
lack
effector
activ
vitro
loss
stimul
vivo
could
detect
elispot
could
also
contribut
differ
tetram
stain
elispot
assay
hobeika
et
al
set
mean
sd
respons
cmv
seroneg
subject
cutoff
valu
found
tetram
stain
elispot
assay
high
sensit
specif
studi
receiv
oper
characterist
roc
curv
analysi
use
determin
cutoff
valu
posit
versu
neg
tetram
score
set
optim
oper
point
show
largest
posit
likelihood
ratio
cutoff
valu
tetram
stain
sensit
specif
rang
tabl
supplementari
materi
among
tetram
stain
high
sensit
specif
cutoff
valu
may
potenti
appli
clinic
assist
diagnost
htnv
infect
demonstr
seven
hlaa
htnv
gp
nonapeptidespecif
ctl
epitop
immunoreact
vitro
next
conduct
htnv
challeng
experi
determin
whether
nonapeptid
immunogen
could
elicit
effect
ctl
respons
htnv
infect
vivo
human
mice
mice
engraft
human
tissu
andor
engin
express
human
gene
mimic
human
immun
speciesrestrict
pathogen
vivo
human
b
tg
mice
express
chimer
gene
consist
domain
hlaa
molecul
transmembran
cytoplasm
domain
b
power
tool
establish
htnv
replic
model
explor
effect
immun
respons
prime
htnv
gpderiv
hlaa
epitop
vivo
vaccin
hlaa
htnv
gp
epitop
significantli
reduc
htnv
antigen
level
rna
load
target
organ
b
tg
mice
compar
tg
mice
inject
pb
immun
control
peptid
htnv
challeng
indic
three
htnv
gp
epitop
could
induc
protect
ctl
respons
inhibit
htnv
replic
might
elicit
similar
effect
human
although
proteom
pathogen
contain
abund
peptid
potenti
act
mhc
irestrict
epitop
ctl
respons
tend
focus
limit
domin
epitop
consid
good
candid
vaccin
tg
mice
lower
htnv
antigen
rna
load
level
compar
tg
mice
even
show
equival
level
kidney
compar
htnv
vaccineimmun
mice
suggest
might
function
immunodomin
epitop
induc
optim
ctl
respons
htnv
infect
previou
studi
indic
hantaviru
gnderiv
epitop
immunodomin
compar
np
gc
consid
protect
antigen
repres
major
candid
genet
engin
vaccin
studi
immunodomin
epitop
also
deriv
gn
subdomin
epitop
locat
region
signal
peptid
gc
respect
thu
immunodomin
gn
interest
find
hantavirus
contain
conserv
tyrosin
residu
near
cterminu
gn
form
immunoreceptor
tyrosin
activ
motif
itam
htnv
could
promot
polyubiquitin
gn
polypeptid
facilit
degrad
via
proteasom
proteasom
gener
epitop
present
mhc
molecul
elicit
ctl
respons
hantaviru
infect
increas
gn
epitop
produc
enhanc
itamregul
degrad
present
cell
surfac
mhc
molecul
epitop
recogn
specif
ctl
induc
highfrequ
ctl
respons
target
cell
might
explain
effect
gnrelat
vaccineinduc
ctl
inhibit
viru
replic
viru
challeng
vivo
peptid
present
mhc
class
molecul
gener
restrict
amino
acid
length
peptid
bind
mhc
allel
share
similar
peptidemotif
contain
certain
anchor
residu
preferenti
util
anchor
mhc
molecul
specif
consensu
peptid
motif
hlaa
peptid
domin
anchor
residu
leucin
l
posit
valin
v
leucin
l
cterminu
interestingli
sequenc
liwtgmidl
rel
conserv
seov
liwrglidl
dobv
liwegyidl
character
invari
primari
anchor
residu
substitut
intern
sequenc
although
intern
sequenc
context
individu
peptid
would
affect
bind
affin
mhc
molecul
either
increas
decreas
bind
affin
substitut
secondari
anchor
amino
acid
posit
seem
limit
effect
immunogen
properti
peptid
encouragingli
demonstr
hlaa
peptid
deriv
influenza
viru
protein
could
elicit
broad
protect
distinct
strain
base
inducedfit
molecular
mimicri
tcr
effect
target
mutat
peptid
henc
possibl
may
induc
ctl
respons
seov
dobv
also
major
caus
agent
hfr
epitop
profession
characterist
lay
foundat
develop
effect
prevent
therapeut
strategi
mixtur
synthet
peptid
deriv
cat
allergen
epitop
success
use
induc
toler
clinic
phase
test
peptid
vaccin
target
angiotensin
ii
recent
develop
novel
treatment
hypertens
prevent
heart
failur
applic
immunodominantepitopebas
cancer
vaccin
combin
strategi
significantli
enhanc
specif
safeti
tcell
respons
target
tumor
hlarestrict
epitop
use
induc
epitopespecif
ctl
respons
elimin
infect
cell
repres
promis
vaccin
strategi
dengu
influenza
viru
infect
identif
htnv
gp
epitop
induc
protect
immun
respons
htnv
infect
b
tg
mice
may
promot
develop
novel
htnv
vaccin
relat
therapeut
method
hfr
notabl
human
kidney
major
target
organ
htnv
frequent
injur
htnv
infect
injuri
may
tcell
immun
htnv
frontier
immunolog
wwwfrontiersinorg
decemb
volum
articl
progress
lethal
aki
higher
level
htnvspecif
ctl
associ
lower
level
blood
urea
nitrogen
creatinin
suggest
htnvspecif
ctl
may
help
reduc
risk
progress
acut
renal
failur
caus
htnv
infect
contribut
reduct
diseas
sever
consid
promin
protect
effect
epitop
kidney
b
tg
mice
possibl
attribut
tendenti
distribut
epitopespecif
ctl
vaccin
may
induc
effect
ctl
respons
prevent
kidney
damag
caus
htnv
infect
human
elucid
cellular
immun
respons
immunodomin
epitop
htnv
benefici
develop
evalu
candid
peptid
vaccin
heterogen
popul
cell
distinct
virusspecif
peptid
stimul
character
differ
multicytokin
secret
profil
prolifer
abil
howev
due
limit
number
cell
perform
function
assay
except
detect
secret
vitro
confirm
epitop
could
induc
function
ctl
sinc
identifi
demonstr
htnv
gnderiv
hlaa
nonapeptid
could
act
immunodomin
epitop
induc
effect
immun
respons
htnv
explor
characterist
ctl
respons
elicit
epitop
futur
studi
togeth
structur
biolog
perform
exampl
xray
crystal
structur
analysi
peptid
complex
summari
first
group
identifi
seven
htnv
gpderiv
hlaa
ninem
ctl
epitop
immunoreact
may
elicit
protect
ctl
respons
patient
hfr
three
chosen
epitop
exhibit
immunogen
character
signific
inhibit
htnv
replic
b
tg
mice
receiv
peptid
vaccin
importantli
epitop
show
power
abil
induc
effect
ctl
respons
htnv
infect
major
target
organ
k
b
tg
mice
especi
promin
protect
effect
kidney
suggest
immunodomin
epitop
could
elicit
specif
clt
respons
elimin
htnv
vivo
result
provid
novel
valuabl
inform
better
understand
ctl
respons
htnv
infect
may
support
diagnosi
immunetarget
hfr
promot
develop
effect
peptid
vaccin
prevent
htnv
infect
human
studi
approv
institut
review
board
fourth
militari
medic
univers
enrol
patient
guardian
sign
inform
consent
form
blood
collect
anim
test
carri
accord
recommend
guid
care
use
laboratori
